RCS - Poolbeg Pharma PLC - Immunomodulator I Patent Portfolio Strengthened

Poolbeg PharmaAnnouncement

20/09/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230920:nRST9827Ma&default-theme=true

RNS Number : 9827M  Poolbeg Pharma PLC  20 September 2023

Poolbeg Pharma plc

 

Immunomodulator I Patent Portfolio Strengthened

Notice of allowance for patent grant in Japan

 

20 September 2023 - Poolbeg Pharma (http://www.poolbegpharma.com/)  (AIM:
POLB, OTCQB: POLBF, 'Poolbeg' or the 'Company'), a clinical-stage
biopharmaceutical company targeting diseases with a high unmet medical need,
announces that it has received a notice of allowance from the Japanese Patent
Office in relation to its Immunomodulator I patent application.

 

The claims deemed allowable cover a p38 MAPK (mitogen-activated protein
kinase) inhibitor for use in the treatment of severe influenza in human
patients and strengthens the Company's robust intellectual property in the
territory. Grant of the application as a patent is expected upon completion of
formalities.

 

Poolbeg has a worldwide licence for POLB 001 for all uses in humans and is
developing a strong IP portfolio with patents in place, including
Immunomodulator I and Immunomodulator II, covering the use of the class of p38
MAP kinase (mitogen-activated protein kinase) inhibitors for the treatment of
severe influenza and hypercytokinaemia. The Company has also filed patent
applications to expand its IP around POLB 001 and the use of p38 MAP kinase
inhibitors in new disease areas, such as oncology. This enhances the value and
attractiveness of POLB 001 to potential pharma partners.

 

Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg Pharma, commented:
"This milestone is a testament to the uniqueness of p38 MAPK inhibition as a
potential blockbuster treatment for severe influenza. We are committed to
continuing to strengthen the intellectual property protection of our portfolio
of assets into new jurisdictions to increase their overall value to potential
partners."

 

Footnote:

Immunomodulator I: Use of p38 MAPK inhibitors for the treatment of severe
influenza

Immunomodulator II: Use of p38 MAPK inhibitors in combination with antiviral
compounds for treatment of severe influenza, and the use of p38 MAPK
inhibitors, alone or in combination with an antiviral agent, for the treatment
of hypercytokinaemia

 

- Ends -

 

Enquiries

 

 Poolbeg Pharma Plc                                                      +44 (0) 207 183 1499

 Jeremy Skillington, CEO

 Ian O'Connell, CFO

 Cavendish Capital Markets Ltd (Nominated Adviser & Joint Broker)        +44 (0) 207 220 0500

 Geoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward (ECM)

 Singer Capital Markets (Joint Broker)                                    +44 (0) 207 496 3000

 Phil Davies, Sam Butcher

 J&E Davy (Joint Broker)                                                 +353 (0) 1 679 6363

 Anthony Farrell, Niall Gilchrist

 Optimum Strategic Communications                                        +44 (0) 208 078 4357

 Nick Bastin, Hana Malik, Vici Rabbetts                                  poolbeg@optimumcomms.com (mailto:poolbeg@optimumcomms.com)

 

About Poolbeg Pharma

Poolbeg Pharma specialises in the development of innovative medicines to
address the unmet need in infectious and other prevalent diseases. Poolbeg
Pharma has a disciplined portfolio approach to mitigate risk, accelerate drug
development, and enhance investor returns. The Company simultaneously advances
multiple programmes in cost-effective clinical trials, rapidly generating
early human safety and efficacy data to enable early partnering /
out-licensing, with the funds generated reinvested in the pipeline. Poolbeg
Pharma also uses AI to interrogate human challenge trial data sets to quickly
identify new targets and drugs, leading to faster development and greater
commercial appeal.

 

The Company is targeting the growing infectious disease market. In the wake of
the COVID-19 pandemic, infectious disease has become one of the fastest
growing pharma markets and is expected to exceed $250bn by 2025. Through
opportunistic identification of assets which complement Poolbeg Pharma's
existing pipeline, the Company is progressing programmes in oncology and
metabolic syndromes; adding disease areas with significant addressable
markets.

 

With its initial assets from hVIVO plc (http://www.hvivo.com/) , an industry
leading infectious disease and human challenge trials business, Poolbeg Pharma
has access to knowledge, experience, and clinical data from over 20 years of
human challenge trials. The Company is using these insights to acquire new
assets as well as reposition clinical stage products, reducing spend and risk.
Amongst its portfolio of exciting assets, Poolbeg Pharma has a small molecule
immunomodulator for severe influenza and other acute inflammatory
conditions (POLB 001) which produces a highly significant reduction in p38
MAP kinase driven cytokines in a clinical setting; a first-in-class,
intranasally administered RNA-based immunotherapy for respiratory virus
infections (POLB 002); and a vaccine candidate for Melioidosis (POLB 003). The
Company is progressing two Artificial Intelligence (AI) Programmes to add
promising new assets to its pipeline as well as developing an Oral Vaccine
Programme and an Oral Delivery Programme focussing on metabolic syndrome
related diseases.

 

For more information, please go to www.poolbegpharma.com
(http://www.poolbegpharma.com/)  or follow us on Twitter
(https://twitter.com/PoolbegPharma)  and LinkedIn
(https://www.linkedin.com/company/poolbeg-pharma/)  @PoolbegPharma.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAVKLFFXKLFBBZ